Information Provided By:
Fly News Breaks for March 15, 2018
ALXN
Mar 15, 2018 | 15:39 EDT
Nomura Instinet analyst Christopher Marai raised his price target on Alexion to $156 after the company announced that the Phase 3 study of ALXN1210 demonstrated non-inferiority to Soliris in complement inhibitor treatment-naive patients with paroxysmal nocturnal hemoglobinuria. He maintains his Buy rating on Alexion shares.
News For ALXN From the Last 2 Days
There are no results for your query ALXN
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.